Dec 20 (Reuters) - Diamedica Inc DMA.V
* Diamedica announces positive top-line results from DM199 bridging clinical trial
* Diamedica Inc says plans to use results of DM199 bridging clinical trial study to guide phase II dosing in upcoming clinical trials
* Diamedica Inc says no treatment limiting adverse events were reported in any dose group in the trial Source text for Eikon: ID:nCCN9DXhNT Further company coverage: DMA.V